Bradley Nelson

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types

Athanasia D. Panopoulos, Matteo D’Antonio, Paola Benaglio et al. · Stem Cell Reports · 2017 · 197 citations · Full text

Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease

Ana Maria Manso, Sherin I. Hashem, Bradley Nelson et al. · Science Translational Medicine · 2020 · 86 citations

Impaired mitophagy facilitates mitochondrial damage in Danon disease

Sherin I. Hashem, Anne N. Murphy, Ajit S. Divakaruni et al. · Journal of Molecular and Cellular Cardiology · 2017 · 70 citations

Mitophagy, Mitochondrial Disease, Mitochondrial Damage +7